Baglaenko, Yuriy
Macfarlane, Dana
Marson, Alexander
Nigrovic, Peter A.
Raychaudhuri, Soumya http://orcid.org/0000-0002-1901-8265
Article History
Accepted: 20 May 2021
First Online: 29 June 2021
Competing interests
: P.A.N. has been supported by investigator-initiated research grants from AbbVie, Bristol-Myers Squibb, Novartis, Pfizer, Sobi; consulting fees from Bristol-Myers Squibb (BMS), Cerecor, Miach Orthopedics, Novartis, Pfizer, Quench Bio, Sigilon, Simcere, Sobi, Exo Therapeutics and XBiotech; royalties from UpToDate Inc.; and salary support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA). A.M. is a compensated co-founder, member of the boards of directors and a member of the scientific advisory boards of Spotlight Therapeutics and Arsenal Biosciences. A.M. was a compensated member of the scientific advisory board at PACT Pharma and was a compensated adviser to Juno Therapeutics and Trizell. A.M. owns stock in Arsenal Biosciences, Spotlight Therapeutics and PACT Pharma. A.M. has received honoraria from Merck and Vertex, a consulting fee from AlphaSights, and is an investor in and informal adviser to Offline Ventures. The Marson lab has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead, and Anthem and reagents from Illumina. A.M. is an inventor on multiple inventions with the Whitehead Institute, UCSF and the Gladstone Institutes, including some that have been licensed. S.R. is a founder for Mestag, Inc, served in the past year as an adviser to Gilead, Biogen, Merck, Pfizer, Janssen and Abbvie. Y.B. and D.M. have no competing interests.